Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas
- PMID:11464855
- DOI: 10.1002/1096-911X(20010101)36:1<1::AID-MPO1002>3.0.CO;2-L
Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas
Abstract
Background: At least three genetic hallmarks identify aggressive tumour behaviour in neuroblastomas; amplification of the oncogene MYCN; deletion (loss of heterozygosity [LOH]) at the short arm of chromosome 1 (del1p36), seen in approximately 28% of the cases; and di-tetraploidy. The MYCN oncogene is amplified in approximately 23% of all neuroblastomas and becomes important for the stratification of therapy in localised and 4s tumours. Up to now, it has been believed that the genetic constellation of neuroblastic tumours is stable and does not alter during tumour evolution or during tumour progression.
Procedure: Using fluorescence in situ hybridisation techniques (FISH) to investigate different tumour areas on touch preparations and histological sections, we show that genetic heterogeneity can be detected in neuroblastomas, especially in tumours detected by urinary mass screening.
Conclusion: The identification of such cell clones is important, because the MYCN amplification and/or the deletion at 1p36 appear to be responsible for aggressive local growth and development of metastases.
Similar articles
- Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.Yong MH, Hwang WS, Knight LA, Fung W, Chan MY, Seow WT, Chui CH.Yong MH, et al.Singapore Med J. 2009 Nov;50(11):1090-4.Singapore Med J. 2009.PMID:19960166
- Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Fukuba I, Matsuura Y, Yokoyama T.Hiyama E, et al.Med Pediatr Oncol. 2001 Jan;36(1):67-74. doi: 10.1002/1096-911X(20010101)36:1<67::AID-MPO1017>3.0.CO;2-S.Med Pediatr Oncol. 2001.PMID:11464909
- Analysis of genomic imprinting at 1p35-36 in neuroblastoma.Hogarty MD, Maris JM, White PS, Guo C, Brodeur GM.Hogarty MD, et al.Med Pediatr Oncol. 2001 Jan;36(1):52-5. doi: 10.1002/1096-911X(20010101)36:1<52::AID-MPO1014>3.0.CO;2-8.Med Pediatr Oncol. 2001.PMID:11464906Review.
- Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections.Leong PK, Thorner P, Yeger H, Ng K, Zhang Z, Squire J.Leong PK, et al.Lab Invest. 1993 Jul;69(1):43-50.Lab Invest. 1993.PMID:8331897
- Neuroblastoma: clinical significance of genetic abnormalities.Brodeur GM.Brodeur GM.Cancer Surv. 1990;9(4):673-88.Cancer Surv. 1990.PMID:2101728Review.
Cited by
- Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.Berbegall AP, et al.Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.Oncogene. 2016.PMID:26119945
- Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics.Ambros IM, Brunner C, Abbasi R, Frech C, Ambros PF.Ambros IM, et al.Front Oncol. 2014 Aug 12;4:202. doi: 10.3389/fonc.2014.00202. eCollection 2014.Front Oncol. 2014.PMID:25161957Free PMC article.
- Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94.Fiedler S, Ambros IM, Glogova E, Benesch M, Urban C, Mayer M, Ebetsberger-Dachs G, Bardi E, Jones N, Gamper A, Meister B, Crazzolara R, Amann G, Dieckmann K, Horcher E, Kerbl R, Brunner-Herglotz B, Ziegler A, Ambros PF, Ladenstein R.Fiedler S, et al.Cancers (Basel). 2021 Feb 2;13(3):572. doi: 10.3390/cancers13030572.Cancers (Basel). 2021.PMID:33540616Free PMC article.
- Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, Martinsson T, Navarro S, Noguera R.Villamón E, et al.PLoS One. 2013;8(1):e53740. doi: 10.1371/journal.pone.0053740. Epub 2013 Jan 14.PLoS One. 2013.PMID:23341988Free PMC article.
- Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, Ribeiro A, Mosseri V, Rubie H, Munzer C, Thomas C, Valteau-Couanet D, Auvrignon A, Plantaz D, Delattre O, Couturier J; Société Française des Cancers de l'Enfant (SFCE).Schleiermacher G, et al.Br J Cancer. 2007 Jul 16;97(2):238-46. doi: 10.1038/sj.bjc.6603820. Epub 2007 Jun 19.Br J Cancer. 2007.PMID:17579628Free PMC article.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Medical